Linezolid Dosing in Renal Impairment (GFR 29 mL/min)
For a patient with GFR 29 mL/min (severe renal impairment), linezolid should be dosed at 300 mg every 12 hours, with treatment duration determined by the specific infection being treated.
Dose Frequency Adjustment
The standard 600 mg every 12 hours dose requires reduction in severe renal impairment. While the FDA label states that linezolid pharmacokinetics are not significantly altered by renal dysfunction, this only applies to the parent drug 1. The critical issue is that two primary metabolites (A and B) accumulate significantly in renal impairment, with metabolite B reaching AUC levels of 203 µg·h/mL in moderate impairment and 467 µg·h/mL in severe impairment (versus 30.5 µg·h/mL in normal function) 1.
Specific Dosing Recommendation:
- 300 mg every 12 hours for your patient with GFR 29 mL/min 2, 3, 4
- Alternative: 450 mg every 24 hours if twice-daily dosing is problematic 4
This dose reduction is supported by multiple recent pharmacokinetic studies showing that:
- Standard dosing (600 mg q12h) results in supratherapeutic trough concentrations (Cmin >8 mg/L) in 60% of patients with renal impairment 3
- The toxicity threshold of Cmin 7.8 mg/L predicts 50% probability of myelosuppression 4
- 300 mg q12h achieves optimal exposure (AUC/MIC ≥100) while maintaining Cmin 2-8 mg/L in 78.6% of patients with CrCL 15-29 mL/min 2
Duration of Therapy
Treatment duration depends entirely on the infection site:
Common Infections:
- Pneumonia: 7-21 days 5
- Skin/soft tissue infections: 7-14 days 6
- Bacteremia (uncomplicated): 2 weeks 5
- Bacteremia (complicated): 4-6 weeks 5
- Septic arthritis: 3-4 weeks 5, 6
- Osteomyelitis: ≥6 weeks 5
- Meningitis: 14 days 5
- Brain abscess/epidural abscess: 4-6 weeks 5
- Endocarditis (native valve): 4-6 weeks 5
- Endocarditis (prosthetic valve): 6 weeks 5
Critical Safety Considerations
Myelosuppression Risk
With your patient's renal function, myelosuppression risk is substantially elevated:
- Median time to myelosuppression: 12 days 4
- Risk increases with Cmin >7.8 mg/L 4
- Monitor complete blood count at baseline, then twice weekly during therapy 3, 4
Therapeutic Drug Monitoring
Strongly recommended in this patient:
- Target trough concentration: 2-8 mg/L 2, 4, 7
- First level: after 3-5 days of therapy
- Adjust dose if Cmin >8 mg/L (reduce to 200 mg q12h) or <2 mg/L (increase cautiously)
Hemodialysis Consideration
If this patient requires hemodialysis (not specified but relevant given GFR 29):
- Linezolid is dialyzable (~30% removed in 3-hour session) 1
- Administer dose after dialysis 1
- Consider 600 mg post-dialysis on dialysis days, 300 mg q12h on non-dialysis days
Common Pitfalls to Avoid
- Do not use standard 600 mg q12h dosing - this virtually guarantees toxic accumulation and myelosuppression in severe renal impairment
- Do not ignore metabolite accumulation - the FDA label's statement about "no dose adjustment needed" is misleading and applies only to parent drug, not metabolites
- Do not extend therapy beyond necessary duration - longer treatment increases myelosuppression risk exponentially
- Do not skip therapeutic drug monitoring - only 18.6% of critically ill patients achieve optimal PK/PD targets with empiric dosing 7